Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Should You Follow Cathie Wood Into This Coronavirus Stock?


Copying someone else's actions isn't always bad, at least when it comes to investing. We have a lot to gain by studying the moves of super-investors, and in some cases, following along. So who should we be looking at these days? Cathie Wood, founder, CEO, and chief investment officer (CIO) of ARK Invest. Wood's exchange-traded funds (ETFs), which include a Genomic Revolution ETF, Fintech Innovation ETF, and a general ARK Innovation ETF (among others), have handily outperformed the S&P 500 over the past year. The funds specialize in innovation in various areas -- from genomics to next-generation internet technologies.

Earlier this month, the ARK Genomic Revolution fund purchased more than 100,000 shares of Regeneron Pharmaceuticals (NASDAQ: REGN). Regeneron, maker of an antibody cocktail to treat COVID-19, is the fund's fourth-biggest holding. Let's take a closer look at Regeneron to see if we should follow superstar investor Wood into this biotech stock.

Image source: Getty Images

Continue reading


Source Fool.com

Like: 0
Share

Comments